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Unresolved inﬂammation is associated with several widely occurring diseases such as
arthritis, periodontal diseases, cancer, and atherosclerosis. Endogenous mechanisms that
curtailexcessiveinﬂammationandpromptitstimelyresolutionareofconsiderableinterest.
In recent years, previously unrecognized chemical mediators derived from polyunsaturated
fatty acids were identiﬁed that control the acute inﬂammatory response by activating local
resolution programs. Among these are the so-called specialized pro-resolving lipid media-
tors (SPMs) that include lipoxins (LX), resolvins (Rv), protectins (PD), and maresins (MaR),
because they are enzymatically biosynthesized during resolution of self-limited inﬂamma-
tion.They each possess distinct chemical structures and regulate cellular pathways by their
ability to activate pro-resolving G-protein coupled receptors (GPCRs) in a stereospeciﬁc
manner.Forinstance,RvD1controlsseveralmiRNAsofinterestinself-limitedacuteinﬂam-
mation that counter-regulate the mediators and proteins that are involved in inﬂammation.
Here, we overview some of the biosynthesis and mechanisms of SPM actions with focus
on the recently reported miR involved in their pro-resolving responses that underscore
their beneﬁcial actions in the regulation of acute inﬂammation and its timely resolution.
The elucidation of these mechanisms operating in vivo to keep acute inﬂammation within
physiologic boundaries as well as stimulate resolution have opened resolution pharma-
cology and many new opportunities to target inﬂammation-related human pathologies via
activating resolution mechanisms.
Keywords: resolution, resolvin, protectin, n-3 PUFA, lipoxin
ACUTE INFLAMMATION: A PROTECTIVE HOST RESPONSE
THAT CAN TURN HARMFUL
Acute inﬂammation is a defensive physiological response occur-
ring in vascularized tissues to protect the host against injuries
(Majno and Joris,1996). This formidable ally manifests its impor-
tantrole,forinstance,intheearlyphaseafteramicrobialinfection,
when it ﬁghts against invading pathogens before the adaptive
immune system is engaged (Abbas et al.,2011). The characteristic
“cardinal signs” of inﬂammation, described by the Roman physi-
cian Celsus in the ﬁrst century, rubor (redness), tumor (swelling),
calor (heat), and dolor (pain), are the macroscopic manifesta-
tion of changes that occur at molecular and cellular levels in
inﬂamed tissues. Tissue edema is one of the earliest events in the
acute inﬂammatory response that arises from increased vascular
permeability of the microvasculature (Figure 1). Leukocytes are
then recruited at sites of inﬂammation and traverse postcapillary
venules. Polymorphonuclear neutrophils (PMN) are among the
ﬁrst leukocyte responders that accumulate in the inﬂamed site.
As they are the ﬁrst line of defense of the innate immune system,
these cells kill pathogens by engulﬁng them via phagocytosis and
release of microbicidal proteins stored in their intracellular gran-
ules and reactive oxygen species into phagolysosomal vacuoles
to kill invaders (Majno and Joris, 1996). Next, in experimental
acute inﬂammation, mononuclear cells enter the inﬂammatory
site. They can differentiate into macrophages (M(s) and clear
microbes, cellular debris, and apoptotic PMN by phagocytosis in
a non-phlogistic process termed efferocytosis (Honn et al., 1989;
Gordon,2007; Serhan et al.,2007).
Ultimately, the clearance and efﬂux of phagocytes allow for
resolution of the tissue and the return to homeostasis, namely
catabasis (Figure 1). In order to maintain a healthy status, both
the initiation of acute inﬂammation and its resolution must be
efﬁcient. Notably, it is not how often or how extensive an acute
inﬂammatory reaction starts, but how effectively and quickly it
resolves that determines whether the battle of inﬂammation is
detrimental or the ideal favorable outcome for the host. Indeed,
uncontrolled or unresolved inﬂammation is now recognized as a
major driver of human pathologies, including arthritis, asthma,
cancers, and cardiovascular diseases (Serhan, 2004; Serhan and
Savill, 2005; Nathan and Ding, 2010). Given the high occur-
rence of these and many other diseases, understanding how acute
inﬂammation resolves is of wide interest.
This review focuses on the specialized pro-resolving media-
tors(SPM)thatarebiosynthesizedfromessentialpolyunsaturated
www.frontiersin.org October 2012 | Volume 3 | Article 298 | 1Recchiuti and Serhan Resolving mechanisms in inﬂammation
Reduce neutrophil infiltration 
Stimulate MF efferocytosis 
Promote tissue regeneration 
Control pain 
Lipid Mediator Class Switch 
Increase edema  
Recruit neutrophils 
Mediate pain 
Initiate/Sustain inflammation 
Lead to chronic  inflammation  
and tissue damage 
SPMs  LTs 
PGs 
Control inflammation  
Expedite resolution and  
return to homeostasis  
Onset  Resolution 
Capillary 
Exudate 
Tissue 
Degranulation 
& Killing 
Efferocytosis & Egress 
PMN Infiltration 
Apoptosis 
tio tio tio tio tio tio tio tio tio tio tio tio
ary y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y
Proresolving 
miRNAs 
Pro-Resolving  
MPs 
SPM 
ue
Onset Phase  Resolution Phase 
FIGURE 1 | Cellular and molecular mediators in acute inﬂammation and
resolution. Surgical intervention, tissue injuries, or microbial infections in
vascularized tissues evoke a rapid acute inﬂammatory response
characterized by a rapid exudate formation with edema, leukocyte inﬁltration,
and serum proteins. Polymorphonuclear leukocytes (PMN) are among the
ﬁrst responders that ﬁght microbes followed by monocytes that differentiate
locally into pro-resolving macrophages (M(s). Efferocytosis of apoptotic
PMN and microbes by pro-resolving M(s and subsequent egress via
lymphatics are hallmarks of tissue resolution. Redness and swelling, two of
the cardinal signs of inﬂammation, can be easily appreciated in the example
of eye and skin inﬂammation shown in the right panel. A few days later,
inﬂammation is almost completely resolved and homeostasis re-established.
(Pictures were taken using a Lumix SZ7 digital camera). Lipid autacoids
prostaglandins (PGs) and leukotrienes (LTs) are classical mediators of the
onset phase of inﬂammation, promoting edema, PMN recruitment, and pain.
By sustaining inﬂammation, PGs and LTs can lead to chronic inﬂammation
and tissue damage. Specialized pro-resolving lipid mediators (SPMs) are
biosynthesized within resolving exudates and proved to be very potent in
reducing further PMN inﬁltration, stimulating non-phlogistic M(
efferocytosis, promoting tissue regeneration, and controlling pain. Recent
advances have demonstrated that speciﬁc miRNAs and microparticles can
possess pro-resolving properties.
fatty acids (PUFAs),arachidonic acid (AA),eicosapentaenoic acid
(EPA), and docosahexaenoic acid (DHA), namely lipoxins (LX),
resolvins (Rv),protectins (PD),and maresins (MaR) and on their
biosynthetic pathways, receptors, and miRNAs that act to control
self-limited inﬂammation and promote its timely resolution. For
readers interested in the biosynthesis of Rv and PD, this subject
was recently reviewed in detail in Bannenberg and Serhan (2010),
and the conﬁrmation and total organic synthesis in Serhan and
Petasis (2011).
RESOLUTION IS AN ACTIVE PROCESS CONTROLLED BY SPM:
SELF-LIMITED EXPERIMENTAL SYSTEM
At the histological level, resolution was well described by pathol-
ogists for more than 100years as the time when the neutrophils
that inﬁltrated the inﬂamed tissue sites leave or are lost from the
site (MajnoandJoris,1996). Traditionally,resolution wasthought
to be a passive process, simply due to the attenuation/dissipation
of chemotactic and pro-inﬂammatory signals. Our results (Ser-
han et al., 2000a; Levy et al., 2001), followed by those from
many others worldwide (reviewed in a consensus report in Ser-
han et al., 2007) demonstrated that resolution is instead an active
process orchestrated by special novel chemical mediators that turn
on biochemical and cellular pathways to enable the return to
homeostasis.
Lipidmediators(LM)fromPUFAplayessentialrolesindistinct
phases of acute inﬂammation, with prostaglandins (PGs; Flower,
2006; Samuelsson, 2012) and cysteinyl leukotrienes (cysLTs) pro-
moting early increase in vascular permeability and leukotriene
(LT) B4 acting as a potent leukocyte chemoattractant (Samuels-
son, 1983). Prostaglandins also contribute to fever and pain
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(von Euler, 1973). Chronic inﬂammation is widely viewed as
an excess of pro-inﬂammatory mediators (Figure 1; Nathan and
Ding, 2010). Results from our laboratory ﬁrst demonstrated that
the resolution phase is characterized by the active biosynthesis
of speciﬁc LM that operate as “resolution agonists” to a) keep
inﬂammation within physiological boundaries and b) expedite
the complete return to homeostasis (Figure 1). The identiﬁca-
tion of this new array of LM was achieved using self-limited
or naturally resolving acute inﬂammation models in vivo and
a systems approach (Serhan et al., 2000a, 2002). The pharma-
cologic impact of the Rv and PD was reviewed in (Serhan
and Chiang, 2008). This new array of LM is now recognized
as a genus of SPM (Serhan and Chiang, 2008) that have two
broad functions and are anti-inﬂammatory and pro-resolving
via stimulating multi-level actions. Accruing evidence indicates
that failure or disruption of the endogenous pro-resolution path-
ways governed by SPM can be detrimental and underlie some
of the mechanisms of chronic inﬂammatory diseases (Gilroy
et al., 1999; Karp et al., 2004; Schwab et al., 2007; Chan and
Moore, 2010). SPM exert their potent dual anti-inﬂammatory
and pro-resolving activities in the low nano- to microgram dose
range when added back into experimental inﬂammatory disease
models (Serhan and Chiang, 2008) and provide biotemplates
for the design of novel therapeutics currently in clinical trials
(see http://Clinicaltrials.Gov Identiﬁer: NCT00799552). There-
fore,harnessing these SPM may provide fascinating opportunities
in the new and uncharted terrain of resolution pharmacology,
with a substantial shift from a depletion pharmacology (i.e., via
inhibitors, blockers, antagonists) toward a new approach based
on resolution agonists that activate endogenous protective and
clearance mechanisms.
Additionalchemicalmediatorsareoperativeininﬂamedtissues
to switch off leukocyte inﬁltration and restore their physiolog-
ical functions. Among these are several cytokines (e.g., TGFb,
IL-10) that accumulate in resolving exudates (Bannenberg et al.,
2005); glucocorticoids and the glucocorticoid-induced annexin-1
protein, which tune the inﬂammatory response and bring about
homeostasis (for a recent review see (Perretti and Dalli, 2009));
and the transcription factor NF-kB, which also carries some
anti-inﬂammatory properties (Lawrence et al., 2001). Moreover,
inducing PMN apoptosis as well as lymphoid cells while stimulat-
ing their prompt removal by M(s also can promote resolution
(Honn et al., 1989; Ariel et al., 2006). Recent results indicate
that small inhibitors of cyclin-dependent kinases fulﬁll this goal
(Leitch et al., 2012) as do annexin-1 peptides (Perretti and Dalli,
2009). Therefore,the resolution process can be pharmacologically
targeted.
Importantly, resolution is not synonymous with endogenous
anti-inﬂammation. This is because, in order to be considered a
“pro-resolver,” a chemical and/or molecular entity, in addition to
servingasa“stopsignal”forneutrophiltrafﬁckingandothercardi-
nalsignsofinﬂammation(e.g.,swelling,pain),mustalsostimulate
efferocytosisbyM(,favortheantibacterialactivities,andpromote
tissuerepairandregenerationtoachievehomeostasis.Alongthese
lines, PGE2 can have anti-inﬂammatory properties in certain set-
tings via stimulation of cAMP, but is not acting as pro-resolver
since it does not enhance the uptake and clearance of apoptotic
cells by M(s (Kunkel et al., 1981). Also, although cyclooxygenase
(COX) inhibitors as well as certain lipoxygenase (LO) inhibitors
reduce some of the cellular events of the inﬂammatory reaction
(e.g., edema formation, PMN recruitment, and pain), they dra-
matically impact the endogenous pro-resolution circuits and may
delay or even derange this ideal outcome of acute inﬂammation
and thus are “resolution toxic” (Gilroy et al., 1999; Schwab et al.,
2007). In contrast, aspirin and glucocorticoids work synergisti-
cally with endogenous pro-resolution pathways (Perretti et al.,
2002).
Complete resolution also requires the clearance of the rem-
nants of damaged tissues and activated or apopotic cells,so-called
microparticles (MPs). Originally viewed merely as empty vesi-
cles, MPs are now recognized as “specialized shuttles” used by
the organism to transfer bioactive molecules from cell to cell.
Their role in inﬂammation and resolution is now being appreci-
ated.Recently,theanti-inﬂammatorypropertiesofaPMN-derived
sub-population of MPs were uncovered, where they appear to
signal to activate resolution mechanisms (Gasser and Schifferli,
2004; Dalli et al., 2008; Norling et al., 2011). Mimicking this
new endogenous mechanism in resolution, novel human PMN-
derived nanoparticles containing AT-RvD1 or a LXA4 stable ana-
log, termed humanized pro-resolving nanomedicines, were pre-
pared. These SPM-enriched nanohumanized particles possessed
beneﬁcial bioactivities in reducing acute inﬂammation in vivo,
expediting resolution, and promoting wound healing (Norling
et al., 2011). Hence, NPs can serve as mimetics of endogenous
pro-resolution pathways (Figure 1).
Activeresolutionincludesgeneexpressionregulationof several
soluble chemical mediators (e.g., cytokines, chemokines), recep-
tors (e.g., Toll-like receptors), as well as transcription factors.
An emerging line of investigation indicates that many genes are
under tight control of miRNAs,short non-coding RNA molecules
that act as translational repressors of mRNA transcripts (Bartel,
2009). They are involved in many physiological and pathological
processes, including cell development, cancer (Iorio and Croce,
2009), and inﬂammation (Sheedy and O’Neill, 2008; Alam and
O’Neill, 2011; O’Neill et al., 2011). Our recent results uncovered
rolesofmiRNAsinself-limitedinﬂammationandintheresolution
phase, speciﬁcally, RvD1-G-protein coupled receptor-dependent
gene networks in resolution of acute inﬂammation as part of the
endogenous circuitry that controls this active process (Recchiuti
et al., 2011; Krishnamoorthy et al., 2012).
IDENTIFYING SPM IN RESOLUTION
An unbiased systems approach was taken to identify the endoge-
nous SPM and decode their mechanisms of action in resolution.
For this, the murine dorsal air pouch and self-limited acute
inﬂammation was ideal because it permitted isolation of con-
tained inﬂammatory exudates (Serhan et al., 2000a, 2002) and
also enabled direct LM lipidomics of bioactive products,as well as
their inactive precursors and further metabolites,proteomics,and
analyses of cellular composition of the resolving exudate; namely
the natural means by which inﬂammation returns to resolution
and homeostasis. With this systems approach it was also possible
to establish the local and temporal dissociation of LM biosyn-
thesis (Bannenberg et al., 2005). For example, upon initiation
www.frontiersin.org October 2012 | Volume 3 | Article 298 | 3Recchiuti and Serhan Resolving mechanisms in inﬂammation
of inﬂammation with TNF-a, there was a typical acute-phase
responsecharacterizedbyrapidPMNinﬁltrationprecededbylocal
generation of both PGs and LTs. Unexpectedly, the eicosanoids
undergo what was termed earlier a “class switch” and the proﬁles
of LM made within this milieu switched with time (Levy et al.,
2001). Indeed, the potent chemoattractants LT were deactivated
and 15-LO required for LX and Rv production was transcription-
ally activated (Levy et al., 2001). Notably, the omega-3 essential
fatty acids DHA and EPA are precursors of Rv, PD, and MaR, are
rapidly carried into the exudates via plasma edema and are then
made available for conversion for the congregated exudate cells
(Kasuga et al., 2008). Of interest, this LM class switching is driven
in part by COX-derived PGE2 and D2, via transcriptional regu-
lation of enzymes involved in LX biosynthesis (Levy et al., 2001).
Hence, the concept that“alpha signals omega,”namely the begin-
ning signals the end in inﬂammation, was introduced by Sir John
Savill and one of us to emphasize this ﬁnding (Serhan and Sav-
ill, 2005) to note that at time zero mediators are biosynthesized
that signal to limit PMN inﬂux and terminate the contained acute
inﬂammatory response.
WHAT IS A LIPID MEDIATOR?
To qualify as a LM,a product must be stereoselective in its actions
and be produced in amounts that are commensurate with its
potency and range of action (Serhan et al., 1996). Along this line,
LX,Rv,and PD are present in human serum in pM to nM amount
(e.g.,LXA4,s1.4nM;RvD1,s50pM;RvE1,s0.5nM;valuesfrom
the Serum Metabolome Project; Psychogios et al., 2011; see also
Oh et al., 2011 for RvE1 and Oh et al., 2012 for RvE2 values)
in human peripheral blood samples from healthy donors. LM
lipidomics using liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) coupled with informatics permit proﬁling of
closely related compounds and identiﬁcation of new molecules.
Retrograde synthesis, both biogenic and total organic, allows the
complete elucidation of chemical structure, stereochemistry, and
physical properties, along with the recapitulation of the in vivo
biosynthetic pathway (for examples see Sun et al., 2007; Serhan
et al., 2009). The matching/identiﬁcation of LM is usually carried
out with at least two different instruments and/or mobile phase
solvent systems and the criteria to identify a known LM are the
following: (a) LC retention time should match by coelution with
the LM authentic standard; (b) UV chromophore should match
thesyntheticandauthenticLM(i.e.,lmax andbandshape);aswell
as (c) 6 diagnostic ions of tandem MS/MS spectrum (Figure2).
Also, the LC-MS/MS fragmentation mechanisms for the Rv and
PDD1andrelatedDHA-derivedproductshavebeenstudiedusing
deuterium-labeled compounds that facilitated their identiﬁcation
in vivo (Hong et al., 2007).
LIPOXINS
Lipoxin A4 and B4 were the ﬁrst anti-inﬂammatory LM recog-
nized to possess pro-resolving actions (Serhan et al., 1984a,b;
Maddox et al., 1997; Takano et al., 1998; Godson et al., 2000).
Although LXs were ﬁrst isolated and identiﬁed in the 1980s in the
Samuelsson laboratory (Serhan et al., 1984a), their potent bioac-
tions were uncovered some years later with the identiﬁcation of
the aspirin-triggered LX (ATL; Claria and Serhan, 1995) and the
design of ATL stable analogs (Serhan et al.,1995;vide infra),when
it became clear that they act as “braking signals” of further PMN
inﬁltration (Takano et al., 1998) and as potent stimuli for the
non-phlogistic recruitment of monocytes (Maddox et al., 1997)
and M( efferocytosis (Godson et al., 2000; recently reviewed in
Serhan,2005;Spite and Serhan,2011). LXs are lipoxygenase inter-
action products derived from the enzymatic conversion of AA
via transcellular biosynthesis during cell–cell interactions occur-
ring during inﬂammation (Samuelsson et al., 1987). In humans,
sequential oxygenation of AA by 15-LO and 5-LO, followed by
enzymatic hydrolysis, leads to the biosynthesis of LXA4 and B4 in
mucosal tissues, such as airways, gastrointestinal tract, and oral
cavity (Edenius et al., 1990; Levy et al., 1993; Gronert et al., 1998;
Figure3 and reviewed in Romano (2010). Blood vessels represent
a second site for LX biosynthesis, with the conversion of 5-LO-
derived LTA4 into LXA4 and B4 by 12-LO in platelets (Serhan and
Sheppard, 1990; Romano and Serhan, 1992; Romano, 2010).
ATL: THE FIRST ASPIRIN-TRIGGERED MEDIATORS
A third LX synthetic pathway is initiated by aspirin, the well-
known derivative of salicylates, by acetylation of COX-2. This
covalentmodiﬁcationshiftstheenzymeactivityfromendoperoxi-
dasetolipoxygenase-like,andCOX-2convertsAAinto15R-HETE,
whichisasubstrateof leukocyte5-LOforthebiosynthesisof 15R-
epi-LXA4 and B4 (Claria and Serhan, 1995). Hence, among the
non-steroidal anti-inﬂammatory drugs (NSAID), aspirin has the
unique capability to “jump start” resolution by its ability to trig-
ger endogenous biosynthesis of so-called “aspirin-triggered” LX
(Figure3)Notably,ATLproducedinvivoinhumansubjectstaking
aspirin (Chiang et al., 2004) proved to mediate the local anti-
inﬂammatory actions of low-dose aspirin in healthy individuals
(Morris et al., 2009).
SPM BIOSYNTHESIZED FROM OMEGA-3 POLYUNSATURATED FATTY
ACIDS: LOCAL MEDIATORS
Theessentialrolesofomega-3PUFAinhealthwereevidentin1929
(BurrandBurr,1929),and&-3,alsoknownasn-3PUFAEPAand
DHA, have beneﬁcial effects in human diseases including poten-
tial antithrombotic, immunoregulatory, and anti-inﬂammatory
properties (Iigo et al., 1997; De Caterina, 2011). Also, the Gruppo
ItalianoperloStudiodellaSopravvivenzanell’InfartoMiocardico-
Prevenzione trial evaluated the effects of &-3 PUFA supplementa-
tionwith>11,000patientssurvivingmyocardialinfarctiontaking
>1gof&-3PUFAdailyalongwithrecommendedpreventivetreat-
ments including aspirin, and reported a signiﬁcant beneﬁt with
a decrease in cardiovascular death (GISSI-Prevenzione Investiga-
tors, 1999). It is believed that the actions of the major lipid of
ﬁsh oil EPA (C20:5) are based upon (a) preventing conversion of
AA to proinﬂammatory and prothrombotic eicosanoids; (b) serv-
ing as an alternate substrate for the ﬁve-series LTs that are less
potent than four-series LTs; and (c) conversion by COX to three-
series prostanoids (i.e., PGI3) that also maintain antithrombotic
actions. These and other explanations offered (Iigo et al., 1997;
Calder,2009;De Caterina,2011) have not been generally accepted
becauseof thelackof molecularevidenceinvivo andthehighcon-
centrations of &-3 PUFA required to achieve putative “beneﬁcial
actions”in in vitro cell culture experiments.
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FIGURE 2 | Strategy for functional proﬁling of SPM in resolving
exudates. (A) During self-limited inﬂammation, murine exudates (a “good
and laudable” pus according to ancient physicians; Majno, 1991) as well as
human leukocytes biosynthesize SPM, which include the lipoxins, E-series
resolvins, D-series resolvins, protectins (neuroprotectin D1), and maresins,
which work to keep the inﬂammatory response within physiological
boundaries and help to expedite the return to homeostasis. Functional
proﬁling takes advantage of liquid chromatography-ultraviolet
spectrometry-tandem mass spectrometry (LC-UV-MS/MS) for identifying and
quantifying SPM. Gas chromatography-mass spectrometry (GC-MS) is also
useful to provide additional information together with LC-UV-MS/MS to
support structural identiﬁcation and proposed structures. Retrograde analysis
with biogenic synthesis using isolated human cells and total organic synthesis
allows the assignment of chirality and double bond geometries using H-NMR
with synthetic materials and matching studies (see text; Fiore et al., 1991;
Serhan et al., 2000a, 2002, 2006, 2012; Sun et al., 2007; Spite et al., 2009a;
Krishnamoorthy et al., 2010 for details). Bioactions of SPM are assessed in
both animal models and human cell systems.They must be stereoselective
and evident at concentrations/doses that are commensurate with the amount
of SPM produced. (B) Example of RvD1 stereoselective total organic
synthesis (reported in Sun et al., 2007); for further details (see Serhan and
Petasis, 2011) for a recent review of organic synthesis.
To address the molecular basis for anti-inﬂammatory proper-
ties of &-3 fatty acids, an unbiased LC-MS/MS-based informatics
approach was developed to identify novel mediators generated
from &-3 precursors during acute inﬂammation in vivo. Using
this approach, EPA and DHA were found to be enzymatically
converted into novel potent LMs coined Rv, an acronym of
resolution phase interaction products, because they: (a) are pro-
duced during cell–cell interactions occurring in the resolution
phase of acute inﬂammatory response; (b) “stop” further neu-
trophil entry to sites of inﬂammation, and (c) reduce exudates
(Serhan et al., 2000a, 2002, 2006; Hong et al., 2003; Bannen-
berg et al., 2005). Rv represented an entirely new family of
mediators produced from the &-3 fatty acids and importantly
they appeared during the resolution phase via active biosyn-
thetic processes. The biosynthesis of Rv gives rise to stereospeciﬁc
local mediators that have potent actions and activate speciﬁc
receptors.
E-SERIES RESOLVINS
EPA-derived E-series Rv are endogenously biosynthesized in vivo
in resolving murine exudates and in isolated human cells systems
byisolatedcells(e.g.,endothelialcell-leukocyteinteraction)andin
wholeblood(videinfra).Thecompletestereochemistryof theﬁrst
member of this family,RvE1,has been established as 5S,12R,18R-
trihydoxy-6Z,8E,10E,14Z,16E-EPA (Arita et al., 2005a). For fur-
ther details on the total organic synthesis (see Serhan and Petasis,
2011). Within vascular endothelial cells, aspirin-acetylated COX-
2 converts EPA into 18R-hydro(peroxy)-eicosapentaenoic acid
(HEPE), which is rapidly taken up by activated leukocytes (e.g.,
PMN) and further metabolized into RvE1. Notably, quantitative
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FIGURE 3 | Biosynthetic schemes of SPM. (A) In humans, AA can be
converted into 15S-H(p)-ETE through 15-LO and into 15R-H(p)-ETE by aspirin
(ASA)-acetylated COX-2. Both intermediates can be further metabolized through
5-LO and enzymatic hydrolysis yielding LXA4 or 15-epi-LXA4. (B) E-series
resolvins are biosynthesized via conversion of EPA by ASA-acetylated COX-2.
Products of these reactions, 18S-H(p)-EPE and 18R-H(p)-EPE, are rapidly taken
up by 5-LO and converted to 18S-RvE1 and RvE1. (C)The DHA metabolome
includes several SPM biosynthesized via 15/5-LO and ASA-acetylated COX-2.
Each SPM is biosynthesized via distinct biochemical routes involving
stereocontrolled oxygenation, epoxide formation, and enzymatic hydrolysis.The
main structures of key SPM and their biosynthetic routes (with precursors and
main enzymes involved) are depicted (see text and Serhan and Petasis, 2011 for
further details).The complete stereochemistry of each of these SPM is
established, total organic synthesis achieved, and bioactions conﬁrmed.
chiral HPLC analysis indicated that the 18R-HEPE isomer was
dominant to its epimer 18S-HEPE in human plasma from healthy
subjects taking EPA (Oh et al.,2011). In contrast,human subjects
who were administered aspirin before EPA had more 18S- than
18R-HEPE,indicatingthataspirinmightpromote18S-HEPEpro-
duction as well as 18R-HEPE from ingested EPA (Oh et al.,2011).
This 18S-HEPE can also be converted to epimeric RvE1 and RvE2
byhumanrecombinant5-LOandLTA4hydrolase(LTA4H),known
aspro-inﬂammatoryLTB4-synthesizingenzymes(Ohetal.,2011).
RvE1 is also produced in vivo through an aspirin-independent
pathwayviacytochromeP450-drivenoxygenationof EPA(Serhan
et al., 2000b). Of interest, RvE1 was also found to be produced
by Candida albicans and appears to be involved in clearance of
this organism (Haas-Stapleton et al.,2007). Thus RvE1 has multi-
ple biosynthetic routes. RvE2 (5S,18-dihydroxy-EPE) is biosyn-
thesized in resolving exudates and in human whole blood via
reduction of 5S-hydroperoxy,18-hydroxy-EPE,an intermediate in
the biosynthetic pathway of RvE1 (Tjonahen et al., 2006; Ogawa
et al., 2009; Oh et al., 2012; Figure 3).
D-SERIES RESOLVINS
Earlier investigations using LC-MS/MS lipidomics of resolving
exudates from mice given DHA and aspirin provided the ﬁrst
evidence of novel endogenous routes that lead to the forma-
tion of 17-hydroxy-containing mediators. Gaining information
on how human tissue and cells may produce D-series Rv involved
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the in vitro recapitulation of biosynthetic pathways using isolated
human cells and recombinant enzymes establishing potential ori-
gins of novel compounds isolated from resolving exudates in vivo.
Along these lines, hypoxic human endothelial cell COX-2 con-
verted DHA to 13-hydroxy-DHA, which switched with ASA to
17R-HDHA.Humanneutrophilstransformed17R-hydroxy-DHA
into two series of di- and trihydroxy products; one initiated via
oxygenation at carbon 7 and the other at carbon 4 (Serhan et al.,
2002). The conversion of 17R-HDHA by human PMNs displayed
similar features as those established for the conversion of AA to
LTB4 or LXs as well as the 18R series of EPA products. These were
termed the “aspirin-triggered” D-series Rv (Serhan et al., 2002).
Remarkably, in the absence of aspirin, D-series Rv carrying the
17S-hydroxy group were identiﬁed in murine exudates and iso-
latedhumancells(Serhanetal.,2002;Hongetal.,2003).Theenzy-
matic pathway leading to the formation of 17S- and 17R-RvD1 is
shown in Figure 3. Following the complete organic synthesis, the
stereochemistry of 17S-,17R-RvD1,and RvD2 were established as
7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-DHA(17S-RvD1),
7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E,19Z-DHA (17R-RvD1;
Sun et al., 2007), and 7S, 16R, 17S-trihydroxy-4Z, 8E, 10Z, 12E,
14E, 19Z-DHA (RvD2; Spite et al., 2009a). Additional members
of this family were identiﬁed (RvD3–RvD6). Each of these arises
bysimilarbiosyntheticroutes,buthasdistinctchemicalstructures
and potentially additional bioactions that are now being unveiled
(Chiangetal.,2012).Importantly,bothRvE1andRvD1wereiden-
tiﬁed in circulating blood of healthy donors by (Psychogios et al.,
2011) as part of the Serum Metabolome Project.
THE (NEURO)PROTECTINS
InadditiontoD-series Rvs,DHAalsoservesasprecursor of anew
family of LM characterized by a conjugated triene system and two
alcohol groups called PD. The name PD accounts for their pro-
tective actions observed in neural tissues and within the immune
system,while the preﬁx neuro PD gives the tissue localization and
siteofaction.Thestructureofthefoundingmemberofthisfamily,
PD1, was ﬁrst disclosed in a report on the isolation and elucida-
tionof Rv(Serhanetal.,2002;Hongetal.,2003),anditscomplete
stereochemistry later established as 10R,17S-dihydroxy-docosa-
4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid (Serhan et al., 2006). In
addition to PD1, several stereo- and positional isomers that also
possess lower bioactivity than PD1 were identiﬁed in human and
mousetissues.Theseinclude10S,17S-diHDHA,4S,17S-diHDHA,
7S,17S-diHDHA,and 22-hydrox-10,17S-docosatriene (a putative
inactivation product of PD1; Serhan et al., 2002; Hong et al.,
2003). The geometry of the double bonds in PD1, their posi-
tions during biosynthesis, and chirality of C10 indicate that PD1
biosynthesis proceeds through a C16(17)-epoxide intermediate
andrequiresspeciﬁcenzymaticstepstogeneratethepotentbioac-
tive molecule from DHA,as conﬁrmed by the isolation of alcohol
trapping products as well as two vicinal diol 16,17-docosatrienes
as minor products of PD1 biosynthesis (Hong et al., 2003; Ser-
han et al., 2006). Recently, a novel aspirin-triggered COX-2 dri-
ven pathway was reported that biosynthesizes the 17R-epimeric
form of PD1 from DHA (Marcheselli et al., 2003; Figure 3). The
total organic synthesis and complete stereochemical assignment
ofAT-PD1(10R,17R-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-
hexaenoic acid) were recently achieved. Both PD1 and AT-PD1
reducedleukocyteinﬁltrationinmurineperitonitis,reducedPMN
transmigration with endothelial cells, and enhanced efferocytosis
of apoptotic PMN by human M( (Serhan et al., 2006). These are
the hallmark actions of a SPM carrying both anti-inﬂammatory
and pro-resolving actions demonstrable both in vitro and in vivo.
MARESINS
M(s have pivotal roles in orchestrating the return to home-
ostasis (Gordon, 2007) and biosynthesize SPM that enhance
their pro-resolving and homeostatic functions. For example, M(
ingesting apoptotic cells initiate the biosynthesis of LXA4, RvE1,
and PD1 but not LTB4 (Freire-de-Lima et al., 2006; Schwab et al.,
2007). In addition, a new family of SPM biosynthesized by M(s
was identiﬁed (Serhan et al., 2009). Unbiased LM LC-MS/MS-
based metabololipidomics during self-limited peritonitis led to
the identiﬁcation of a novel pathway that converted DHA into
14-hydroxy DHA (HDHA). Experiments with 12/15-LO /  mice
or with LO inhibitor conﬁrmed that 14-HDHA production was
via a DHA carbon 14 lipoxygenation pathway. Freshly prepared
14-H(p)DHA is rapidly converted by isolated human and mouse
M( into a new set of bioactive products, whose molecular struc-
turewasestablished(Serhanetal.,2009)andrecentlyconﬁrmedby
matchingofbiogenicmaterialwiththosepreparedbytotalorganic
synthesis(Serhanetal.,2012).Themajorproductofthisnewpath-
way proved to be 7,14-dihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z-
hexaenoic acid,denoted MaR (macrophage mediator in resolving
inﬂammation) 1 (ﬁrst in the family; MaR1; Serhan et al., 2009).
Similar to that of other potent SPM, MaR1 biosynthesis proceeds
via an epoxide intermediate, speciﬁcally the MaR1 13,14-epoxide
intermediate, that was demonstrated by trapping experiment and
with18O-containingmolecularoxygenO2 thatopensduringenzy-
maticconversiontoMaR1keepingthedoublebondgeometryand
chirality of carbon 7 and 14.
In addition to MaR1 in resolving murine exudates, a novel
double dioxygenation product was isolated and identiﬁed,
7S,14S-dihydroxydocosa-4Z,8E,10Z,12E,16Z,19Z-hexaenoic acid
(denoted 7S,14S-diHDHA), formed by consecutive lipoxygena-
tion of 14-HDHA, was also identiﬁed using molecular oxygen
incorporation,andprovedbioactivebutlesspotentinactivitythan
MaR1 in stimulating efferocytosis with human cells (Serhan et al.,
2009,2012). MaR1 and RvE1 are also potent stimulators of organ
regeneration using a planaria regeneration system (Serhan et al.,
2012). Hence, SPM are primordial molecules that signal from the
inﬂammatory site to generate the aftermath of inﬂammation and
tissue injury.
GPCRsFORSPMINANTI-INFLAMMATIONANDRESOLUTION
GPCRs FOR LXs
The ﬁrst evidence for receptor-mediated actions of LXA4 arises
fromstudieswithSantoshNigamwhenhewasonsabbaticalinthe
SerhanLabatBWHinthelate1980s,whichdemonstratedstimula-
tion of rapid lipid remodeling and pertussis toxin (PTX)-sensitive
release of arachidonate in PMN treated with LXA4 (Nigam et al.,
1990). To examine the molecular basis of these actions, synthetic
[11,12-3H]-LXA4 was prepared and used to demonstrate speciﬁc
and reversible binding to intact human PMN with a Kd s0.5nM.
[3H]-LXA4 bindingwasstereoselectiveasLXB4,LTB4,6S-LXA4,or
11-trans-LXA4 did not compete for LXA4 binding,while cysteinyl
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LT C4 and D4 partially displaced bound labeled LXA4 (Fiore et al.,
1992).ScreeningofcDNAclonesfromdifferentiatedHL60human
cells lines led to the identiﬁcation of formyl peptide receptor like-
1, a homolog of formyl receptor, as putative LXA4 GPCR (Fiore
et al., 1994). This receptor has recently been coined ALX/FPR2
by the international nomenclature committee in light of its high
afﬁnity for LXA4 (Ye et al., 2009).
Human FPR2/ALX is highly expressed in myeloid cells and at
a lower extent in lymphocytes, dendritic cells, and resident cells
(Chiang et al., 2006). Orthologs of the human FPR2/ALX have
been identiﬁed in mice (Takano et al., 1997) and rats (Chiang
et al., 2003). In addition to LXA4, FPR2/ALX is activated by the
glucocorticoid-inducedproteinannexin-1anditsN-terminalpep-
tides (Perretti et al., 2002), representing the prototype of GPCR
able to coordinate anti-inﬂammatory and pro-resolving activi-
ties of both lipid and peptide ligands. Genetic manipulation of
ALX/FPR2 and its ortholog in mice has provided evidence for
the essential role of this GPCR in controlling immune responses.
Indeed, myeloid-driven overexpression of human FPR2/ALX in
transgenic mice resulted in a reduced neutrophil inﬁltration dur-
ing zymosan-induced peritonitis (Devchand et al.,2003),whereas
ALX/FPR2 /  micehaveanexacerbatedinﬂammatoryphenotype
and delayed resolution (Dufton et al., 2010).
More strikingly, ATL and FPR2/ALX expression levels dic-
tate both the magnitude and duration of acute inﬂammation in
humans(Morrisetal.,2010).Hence,mechanismsthatregulatethis
expression are of wide interest. Recent results from Simiele et al.
(2012) uncovered the molecular basis of ALX/FPR2 transcription
machinery,with the identiﬁcation of the core promoter sequence,
the elucidation of transcription factors and epigenetic mecha-
nismsthatregulatepromoteractivity,andtheidentiﬁcationof the
ﬁrst inheritable SNP that impairs promoter activity in individuals
at high cardiovascular risk. Notably,LXA4 upregulatesALX/FPR2
levels by activating its promoter, suggesting an additional mecha-
nism by which LXA4 exerts its bioactivities (Simiele et al., 2012).
This is particularly relevant in considering LX roles in stimulating
resolution. In addition, earlier studies demonstrated that radiola-
beled 15-epi-LXA4 binds at cysteinyl LT receptor 1 (CysLT1) with
equal afﬁnity to LTD4, providing additional molecular mecha-
nisms forATL dampening CysLT signals in the vasculature as well
as regulating leukocyte trafﬁcking via ALX/FPR2 (Gronert et al.,
2001).
GPCRs FOR E-SERIES RESOLVINS
AtleasttwoGPCRsareinvolvedinmediatingRvE1actions,namely
ChemR23 and BLT1 (Arita et al., 2005a, 2007). RvE1 binding to
ChemR23 was assessed with [3H]-labeled RvE1, which was pre-
paredbycatalytichydrogenationfromsyntheticdiacetylenicRvE1.
[3H]-RvE1 bound to ChemR23 transfectants with high afﬁnity
(Kd D11.35.4nM) and stereoselectivity, since RvE1 biogenic
precursors EPA and 18R-HEPE did not compete with [3H]-RvE1.
Also,the synthetic peptide fragment (YHSFFFPGQFAFS) derived
from human chemerin that was earlier reported to be a ligand for
this same receptor (Wittamer et al., 2003) displaced [3H]-RvE1
bindingbys70%whentestedat10mMconcentration,suggesting
that RvE1 and chemerin share recognition sites on ChemR23
(Aritaetal.,2005a;Ohiraetal.,2009).[3H]-RvE1speciﬁcbinding
was also demonstrated with membrane fractions isolated from
human PMN. Radiolabeled RvE1 bound human PMN with Kd
of s50nMandwasdisplacedbyhomoligandRvE1(Ki s34nM),
LTB4 (Ki D0.08nM),and LTB4 receptor 1 (BLT1) selective antag-
onist U-75302 (Ki D1.5nM), but not by the chemerin peptide
(Arita et al., 2007). These results strikingly demonstrated that
RvE1 binding sites are pharmacologically distinct from ChemR23
on human PMN and prompted us to investigate whether RvE1
binds to LTB4 receptors.
In these studies, Arita et al. found that [3H]-RvE1 also gave
high afﬁnity binding to recombinant BLT1 (Kd s45nM) that
was competed by unlabeled LTB4 (Ki D3nM). In contrast,BLT2-
overexpressing cells did not show [3H]-RvE1 binding at concen-
trationsupto10nM.TheseresultsclearlydemonstratedthatRvE1
bindstoBLT1onhumanPMNandactsasapartialagonisttoatten-
uate LTB4 incoming signals in both mouse and human leukocytes
(Arita et al., 2007).
Proﬁling for tissue distribution of human ChemR23 showed
expressionof thisGPCRinbrain,kidney,cardiovascular,gastroin-
testinal, and myeloid tissues (Arita et al., 2005a). More recently,
direct evidence for ligand-receptor interactions of RvE1 and its
epimer 18S-RvE1 was provided using ChemR23 and BLT1 b-
arrestincells.Inthissystem,cellswereengineeredtoco-expressab-
arrestin protein tagged with an inactive moiety of b-galactosidase
enzyme together with a candidate GPCR fused to the short Pro-
Link peptide derived from b-galactosidase. In the presence of lig-
and,inthiscontextRvE1activatesGPCRinteractswithb-arrestin,
bringing to proximity two inactive portions of b-galactosidase
and reconstituting the fully active enzyme. The activity of this
enzyme, which is stoichiometrically dependent on GPCR-ligand
interaction,ismonitoredwithachemiluminescencedetectionsys-
tem. With ChemR23 b-arrestin cells,18S-RvE1 dose-dependently
activated ChemR23 receptor, with EC50 (s6.3pM) lower than
that obtained with RvE1 (s0.14nM). 18S-RvE1 also antago-
nized LTB4-mediated BLT1 activation with higher potency and
efﬁcacy than RvE1 in BLT1 b-arrestin cells (Oh et al., 2011).
Hence, RvE1 and 18S-RvE1 can share the same site(s) of spe-
ciﬁcbindingtohumanChemR23aswellasBLT1andthussuggest
location-dependent mechanisms in their signaling capabilities.
RvE2 exerts potent and cell-speciﬁc bioactions on human
leukocytes (Tjonahen et al., 2006; Oh et al., 2012). Recently,
tritium-labeled [3H]-RvE2 was synthesized and gave comparable
Kd (s25nM) with other SPM in isolated human PMN. In addi-
tion, using ChemR23 and BLT1 b-arrestin cells, RvE2 was found
to share, at least in part, receptors with RvE1 (Oh et al., 2012).
GPCRs FOR D-SERIES RESOLVINS
RvD1 activates its own GPCR and does not activate ChemR23.
RvD1 exerts speciﬁc bioactivities on human PMN,namely reduc-
tion of F-actin polymerization, that are inhibited by PTX but
not cholera toxin, whereas it did not stimulate Ca2C release nor
activate cAMP in human PMN (Krishnamoorthy et al., 2010).
For the purpose of investigating direct binding of RvD1 to
human PMN, [3H]-RvD1 was prepared by catalytic hydrogena-
tion of synthetic [13,14]-acetylenic RvD1 methyl ester by custom
tritiation (American Radiolabel; Krishnamoorthy et al., 2010).
This procedure was followed by de-esteriﬁcation and isolation of
the RvD1 label using RP-HPLC. [3H]-RvD1 speciﬁcally bound to
humanPMNwithhighafﬁnity(Kd s0.17nM)andwascompeted
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by homoligand cold RvD1 (100%) and LXA4 (s60%) but not
the ALX-ligand annexin-1-derived Ac2-12 peptide. In parallel,
[3H]-RvD1 also showed speciﬁc binding with human monocytes
(Krishnamoorthy et al., 2010). Since RvD1 counteracts TNF-a
in vivo, luciferase-based reporter system (Arita et al., 2005a) was
employed in functional screenings to assess the ability of selected
GPCRs (Figure 4) to transduce RvD1 signals that block NF-kB
activity in response to TNF-a.
Phylogenetically related GPCR linked to inﬂammation and
chemoattraction were overexpressed into HeLa cells together
with a reporter vector consisting of NF-kB promoter sequence
linked to the luciferase gene. RvD1 signiﬁcantly reduced TNF-
a-stimulated NF-kB response in cells overexpressing either the
LX receptor ALX/FPR2 or the orphan, GPR32, but not other
GPCRs(e.g.,BLT1,BLT2,CB1,GPR-1,FPR,andChemR23;Krish-
namoorthy et al., 2010). Moreover, RvD1 dose-dependently acti-
vated ALX/FPR2 and GPR32 in recombinant b-arrestin cells with
EC50 in the low picomolar range (EC50 s1.2pM for ALX/FPR2;
8.8pM for GPR32; Figure 5). In contrast, RvD1 did not acti-
vate RvE1 receptor ChemR23, demonstrating the high selectivity
of these ligands for their speciﬁc GPCR (Krishnamoorthy et al.,
2010). In comparison, at equimolar concentrations, RvD1, its
epimer AT-RvD1, RvD1-carboxy-methyl ester, and a metaboli-
callymorestableanalog17(R/S)-methylRvD1-MEactivatedboth
ALX/FPR2 and GPR32 with similar potencies and EC50, whereas
thebiosyntheticprecursornativeDHAwasnotactivewithGPR32
and ALX/FPR2 in this concentration (Krishnamoorthy et al.,
2012). Of interest, the known anti-inﬂammatory ALX/FPR2 ago-
nist compound 43 identiﬁed by traditional medicinal chemistry
screening also activated GPR32 (EC50 s2.2pM) and ALX/FPR2
(EC50 s2.0pM)inb-arrestincellsbutnottheADPreceptorP2Y12
(Krishnamoorthy et al., 2010). Hence, RvD1, AT-RvD1, and the
derivatives carboxy methyl ester and 17(R/S)-RvD1 directly acti-
vate ALX/FPR2 and GPR32, hereafter referred to as RvD1 recep-
tor (DRV1) following the IUPAC recommendations for recep-
tor nomenclature (Brink et al., 2003; Figure 5). Overexpression
of either ALX/FPR2 or GPR32 in human M(s gave further
enhancement of efferocytosis in response to RvD1, while knock-
down of ALX/FPR2 or DRV1/GPR32 determined a decrease in
RvD1-stimulated phagocytosis response (Krishnamoorthy et al.,
2010).
In keeping with this, Norling et al. (2012) demonstrated that
the ability of RvD1 to reduce human PMN-endothelial cell inter-
actions is absolutely dependent on ALX/FPR2 and DRV1/GPR32.
Interestingly, actions of low concentration (1nM) RvD1 were
dampened by DRV1/GPR32 blocking antibody, whereas at high
concentrations (10nM) they appeared ALX/FPR2-speciﬁc. These
tworeceptorsalsohavedistinctresponsesinanactivatedcellenvi-
ronment in that upon activation human PMN rapidly mobilized
ALX/FPR2 stored in secretory granules, but not DRV1/GPR32,
to the cell membrane. In addition, in ALX/FPR2 knockout mice
RvD1 did not exert anti-inﬂammatory (e.g., stop PMN inﬁltra-
tion)norpro-resolving(e.g.,enhancingM(efferocytosis)actions
(Norling et al., 2012). Hence, speciﬁc GPCRs selectively mediate
RvD1 actions with ALX/FPR2 being rapidly upregulated in PMN
that are exposed to pro-inﬂammatory stimuli and DRV1/GPR32
possibly conveying more homeostatic functions. With respect to
cell and tissue distribution, ALX/FPR2 is present on leukocytes
and resident cells (including M(, synovial ﬁbroblasts, mesangial
cells,endothelial,andepithelialcells;Krishnamoorthyetal.,2010).
Human DRV1/GPR32 was identiﬁed in peripheral blood leuko-
cytes and arterial and venous tissues using a cDNA array. It is
mostly abundant on PMN, monocytes, and macrophages and is
also present on vascular endothelial cells (Krishnamoorthy et al.,
2010). The murine ortholog of DRV1/GPR32 is currently not
known but is present in chimpanzees. Regulatory mechanisms
of DRV1/GPR32 are of interest while those of ALX/FPR2 have
recently been uncovered (Simiele et al., 2012). Although speciﬁc
receptors for RvD2, RvD3, and RvD4 have not yet been identi-
ﬁed, the stereoselective actions of RvD2 were inhibited by PTX
(Spite et al.,2009a),implicating the involvement of GPCRs. More
recently,Chiangetal.(2012)reportedactivationofRvD1-receptor
DRV1/GPR32 by RvD5,which is related biosynthetically to RvD1,
with the recombinant human DRV1.
GPCRs FOR NEURO (N)PD1/PD1
Biosynthesis of (N)PD1 occurs in neural tissues in response to
injury, ischemia-reperfusion, and exposure to b-amyloid pep-
tides (Marcheselli et al., 2003; Mukherjee et al., 2004; Bazan,
2007). In addition (N)PD1 shows protective anti-inﬂammatory
andpro-resolvingactionswithintheimmunesystem(Serhanetal.,
2002; Hong et al., 2003). Hence, it was of interest to determine
the molecular basis of (N)PD1/PD1 actions. Speciﬁc binding of
tritium-labeled (N)PD1 obtained by catalytic tritiation of syn-
thetic 15-acetylenic NPD1 methyl ester was demonstrated with
both retinal pigment cells (RPE) and human PMN. [3H]-(N)PD1
bound RPE with Kd s30pmol/mg of cell protein. However, at
high concentration of radio-ligand (>10nM), non-speciﬁc bind-
ing was evident, in line with the highly hydrophobic nature of
thiscompound.Intheseexperiments,competitivebindingstudies
with unlabeled ligand demonstrated 90–100% displacement for
the free acid form of cold (N)PD1. In these studies (N)PD1-ME
showed a lower afﬁnity for binding sites and s74% displace-
ment, while other structurally related omega-3 fatty acid-derived
compounds (17S-hydroxy-DHA, RvE1, D15-trans-NPD1, and
D15-trans-NPD1-carboxy methyl ester) gave only minimal or no
displacement. Speciﬁc binding experiments with [3H]-NPD1 and
isolated human PMN proved high afﬁnity speciﬁc binding and
showed a two-site ﬁt for sites of high and low afﬁnity binding
(Kd 25and200nM).TwootherSPMthatbindspeciﬁcreceptors
onhumanPMN,namelyLXA4 (LXA4)andRvE1,didnotcompete
with [3H]-NPD1 binding on these cells (Marcheselli et al., 2010).
HOW DO THE PRO-RESOLVING MEDIATORS WORK?
By deﬁnition, SPM: (a) are generated within the resolution
phase; (b) limit leukocyte inﬁltration; (c) enhance phago-
cytic activity of pro-resolving M( to remove apoptotic cells
and/or microbes; (d) stimulate the clearance of PMN from
mucosal surfaces and their anti-microbial actions. If a LM
fulﬁlls each of these bioactivities, then it belongs to the
genus of SPM. At the cellular and molecular levels, SPM dis-
play distinct modes of action on PMN and monocyte/M(s,
which can be demonstrated with isolated cells. Each SPM
(RvE1, RvE2, and RvD1) stimulates a rapid shape change of
human leukocytes that reﬂects ligand-receptor responses and
cytoskeletal events that ultimately limit the PMN to diapedesis
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FIGURE 4 | Identiﬁcation of RvD1 GPCR. (A) Phylogenetic tree shows
similarities in the amino acid sequences of human GPCRs closely related to
LXA4, RvE1, and LTB4 receptors (left panel). Cluster was generated with the
ClustalW2 software (www.ebi.ac.uk/Tools/clustalw2). Protein sequences
were deduced from the NCBI database and receptor nomenclature followed
the IUPAR classiﬁcation for GPCR. (B) For functional screening and
identiﬁcation of RvD1 receptor, GPCRs were cloned in pcDNA3 vector and
overexpressed in human HeLa cells cotransfected with pNF-kB luciferase
plasmid. Cells were treated with RvD1 andTNF-a (see inset in the right panel).
RvD1 reducesTNF-a-stimulated NF-kB activation in DRV1/GPR32 and
ALX/FPR2 receptor-overexpressing cells, while cells transfected with other
related GPCRs (e.g., BLT1, BLT2, CB1, GPR-1, FPR, and ChemR23) did not
signiﬁcantly inhibitTNF-a-induced NF-kB luciferase activity on addition of the
ligand RvD1.The results illustrated are expressed in luminescence units
subtracted from pNF-kB and pcDNA3 empty vector (*P <0.05 vs.
BLT2-transfected cells).
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FIGURE 5 | Structure-activity relationship of RvD1,AT-RvD1, and
DHA onALX/FPR2 and DRV1/GPR32 receptors. Activation of
ALX/FPR2 and DRV1/GPR32 was determined using the b-arrestin cell
system.This system is engineered by stably expressing the target
ALX/FPR2 or DRV1/GPR32 tagged with the b-galactosidase Pro-Link
peptide. Cells also co-expressed the b-arrestin protein linked to the
b-galactosidase EA fragment. In the presence of ligand, activated GPCR
interacts with b-arrestin, bringing to proximity the EA and Pro-Link
fragments, forming a functional enzyme. b-galactosidase activity is
measured by adding the substrate and generating a chemiluminescent
signal that is stoichiometrically associated to ligand dependent GPCR
activation (see text and Krishnamoorthy et al., 2010 for further details).
Dose-response curves show activation of ALX/FPR2 (A) and
DRV1/GPR32 (B) receptors by RvD1, AT-RvD1, but not DHA determined
using the b-arrestin cell system. Results are mean (SEM) from nD4
to 6. RLU, relative luminescence unit.
in vivo, hence reducing inﬂammation and tissue damage (Dona
et al., 2008; Kasuga et al., 2008; Oh et al., 2012) and pre-
pare the macrophages to enhance phagocytosis of both apop-
totic cells and microbes (Schwab et al., 2007; Ohira et al.,
2009).
The best examples of these pro-resolving cellular mechanisms
studiedtodatearefortheRvligandsRvE1andRvD1.Inthecaseof
RvE1,itsdirectbindingtothehumanrecombinantGPCRdenoted
ChemR23, an RvE1 receptor, activates the receptor with the sub-
sequent regulation of Akt intracellular signaling pathway and
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phosphorylation signaling of proteins that increase phagocytosis
(Ohira et al., 2009). In the case of RvD1, the ligand reduces actin
polymerization in isolated human PMN in a PTX-sensitive man-
ner (Krishnamoorthy et al., 2010), diminishes surface expression
of CD11b involved in leukocyte adhesion to endothelial cells
(Krishnamoorthy et al., 2010) as does RvE1 (Dona et al., 2008),
evokes a shape change and stops chemoattractant-initiated PMN
migration observable at a single cell level with human cells iso-
lated within microﬂuidic chamber systems (Kasuga et al., 2008).
Of note, LXA4 also stops PMN chemotaxis in vitro (reviewed in
Serhan, 2005), while it induces rapid activation of small GTPases
and redistribution of cytoskeletal proteins (e.g., MYH9, F-actin)
inhumanmonocyte-derivedM(sduringphagocytosis(Maderna
etal.,2002;Revilleetal.,2006).Hence,thereappearstobeageneral
mechanismonhowpro-resolvingmoleculesworktoachievetheir
potent anti-inﬂammatory and pro-resolution actions, namely
via SPM coupling to distinct high afﬁnity receptors that evoke
cell-type and speciﬁc intracellular pathways.
Besides these general actions, each SPM possesses additional
speciﬁc activities (see Table 1; Fredman and Serhan, 2011). Given
the important protective function of acute inﬂammation to ﬁght
infections or dangers from within and the need to safeguard
the host from an uncontrolled reaction, it is not surprising that
SPM have some bioactions overlapping in target tissues and spe-
ciﬁc cell types. In addition, the sites of biosynthesis for each
SPM and the degree of cell distribution of their GPCRs may
underlie selectivity and speciﬁcity of the pro-resolving system.
In experimental models of inﬂammation and resolution, SPM
proved to be stereoselectively active in the nano- to low micro-
gram dose range to control inﬂammation, limit tissue damage,
shorten resolution intervals, promote healing, and alleviate pain
(Table 1). In order to deﬁne resolution in unbiased, quantitative
terms,mathematical resolution indices were introduced for deter-
mining the cellular changes in exudates, i.e., Tmax, time point
of maximum PMN inﬁltration ()max); T50, time necessary to
achieve 50% reduction in PMN number ()50) from )max; res-
olution interval (Ri DT50  Tmax), time interval between Tmax
and T50 (Bannenberg et al., 2005). The introduction of reso-
lution indices permits the evaluation of pro-resolution bioac-
tions of endogenous chemical mediators or pharmacological
agents (Schwab et al., 2007; Haworth et al., 2008; Navarro-Xavier
et al., 2010). These results ﬁrst demonstrate the possibility to
pharmacologically manipulate resolution and stimulate resolu-
tion. Along these lines, results from the ﬁrst human Phase I–
II clinical trials demonstrated the safety and efﬁcacy of a Rv
analog that reduces both signs and symptoms of dry eye syn-
drome (http://Clinicaltrials.Gov Identiﬁer: NCT00799552) and
have moved forward to Phase III clinical trial with Celtic Ther-
apeutics. Dye eye syndrome is a chronic illness commonly treated
with the immune-suppressant cyclosporine, providing evidence
that SPM have the potential to treat a broad array of human
diseases.
Acute inﬂammation following tissue injury, surgery, or infec-
tionscausespain(MajnoandJoris,1996).Peripheralsensitization
ofprimarysensoryneuronsisinducedbyinﬂammatorymediators
released after tissue insults, such as bradykinin, prostaglandins,
nerve growth factors (NGF), pro-inﬂammatory cytokines such
as TNF-a, interleukin (IL)-1b and IL-6, and pro-inﬂammatory
chemokines (Stein et al., 2009). The contribution of PGE2 and I2
led to the use of NSAID (e.g., naproxen, ibuprofen) and selective
COX-2 inhibitors as analgesic. Since SPM are potent regulators of
acute inﬂammation and pro-inﬂammatory mediators (including
PGs,TNF-a,andIL-1b),andsinceCOX-2inhibitorsareresolution
toxic (Schwab et al.,2007),it was of interest to investigate whether
SPMcouldcontrolinﬂammationassociatedandchronicpain.The
initial report from Svensson et al. (2007) on the antinociceptive
actions of LXA4 was followed by further studies demonstrat-
ing that Rvs, PD, and also MaR1 have potent analgesic activities
whenadministeredbothlocallyandsystematically(Xuetal.,2010;
Huang et al., 2011; Lima-Garcia et al., 2011; Park et al., 2011; Ser-
han et al., 2012). Notably, the exquisite potent actions of SPM,
which proved as effective as morphine and COX-2 inhibitor NS-
398 at much lower doses (Xu et al., 2010), occur without altering
basal sensitive perception, unlike other anesthetics used to con-
trol pain during surgery. Hence it appears possible to resolve pain
signaling as well as inﬂammation.
Complete resolution requires regeneration of destroyed tissues
without affecting their functionality as in the case of ﬁbrosis or
scarring. Pro-resolving M( play key functions in tissue remodel-
ing under both homeostatic (e.g.,post parturition) and patholog-
ical (e.g., removal of microbes from infected tissues) conditions
(Honn et al., 1989; Majno and Joris, 1996; Gordon, 2007). In this
regard, SPM are of considerable interest in view of their roles in
regulating M( activities. For instance, LX, Rv, and PD stimu-
late the non-phlogistic efferocytosis by M( (Godson et al., 2000;
Schwab et al., 2007; Hong et al., 2008; Krishnamoorthy et al.,
2010; Oh et al., 2011). In addition, RvD1 regulates M( accumu-
lation in diabetic obese mice (Hellmann et al., 2011) and reduces
arthritic pain (Xu et al., 2010; Lima-Garcia et al., 2011). Failure
in the M(-driven pro-resolution program can support persis-
tent inﬂammation associated with many human diseases, such as
periodontitis. In keeping with this, recent reports indicate that
M( from localized aggressive periodontitis have impaired phago-
cytosis and persistent inﬂammation that is rescued with RvE1
(Fredman et al., 2011). In addition to enhancing M( phagocy-
tosis,MaR1 biosynthesized in vivo during tissue injury repair also
accelerated tissue regeneration in planaria (D. tigrina) after sur-
gical head removal (Serhan et al., 2012). Of note, these actions of
MaR1wereinhibitedbyPTX,indicatingtheinvolvementof GPCR
and related signaling in this process (Serhan et al., 2012).
miRNAs IN RESOLUTION CIRCUITS
Results from the Serhan laboratory at Brigham and Women’s
Hospital-Harvard Medical School demonstrated for the ﬁrst time
that SPM are operative in resolution and act locally to control
leukocyte trafﬁcking,regulate chemical mediators (e.g.,cytokines,
chemokines, and lipid autacoids), and expedite the return to
homeostasis.SincemicroRNA(miRNAs)haveemergedastheﬁne
tuners of many cellular processes, including immune responses
and cancer, it was of interest to investigate whether they also
played roles in resolution and SPM-regulated speciﬁc miRNA
as part of their mechanisms of action. To identify a miRNA
signature of resolution in self-resolving exudates, a strategy with
resolving exudates from murine peritonitis was used (Figure 6).
Zymosan A particles from S. cerevisiae, a Toll-like receptor 2 and
4 ligand, were injected i.p. and peritoneal exudates collected to
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Table 1 | Bioactions of SPM.
SPM Disease model Mechanism of action Reference
Lipoxin A4/ATL Mouse/dermal inﬂammation Inhibits neutrophil recruitment and vascular leakage Takano et al. (1997)
Mouse/dorsal air pouch Inhibits neutrophil recruitment Clish et al. (1999)
Rabbit/periodontitis Reduces PMN inﬁltration and prevents connective
tissue and bone loss
Serhan et al. (2003)
Mouse/peritonitis Inhibits neutrophil recruitment and lymphatic removal of
phagocytes
Bannenberg et al. (2005) and
Schwab et al. (2007)
Mouse/colitis Attenuates pro-inﬂammatory gene expression and
reduces severity of colitis, inhibits weight loss,
inﬂammation, and immune dysfunction
Gewirtz et al. (2002)
Mouse/asthma Inhibits airway hyper-responsiveness and pulmonary
inﬂammation
Levy et al. (2002)
Mouse/cystic ﬁbrosis Decreases neutrophilic inﬂammation, pulmonary
bacterial burden, and disease severity
Karp et al. (2004)
Mouse/ischemia/reperfusion (I/R) Attenuates hind limb I/R-induced lung injury.
Detachment of adherent leukocytes in mesenteric I/R
vessels. Reduces myocardial infarct size and area at risk
in myocardial I/R
Scalia et al. (1997) and Chiang
et al. (1999)
Mouse/cornea Accelerates cornea re-epithelialization, limits sequelae
of thermal injury (i.e., neovascularization, opacity) and
promotes host defense
Gronert et al. (2005)
Mouse/angiogenesis Reduces angiogenic phenotype: endothelial cell
proliferation and migration
Fierro et al. (2002)
Mouse/bone marrow transplant (BMT) Protects against BMT-induced graft-versus-host
diseases (GvHD)
Devchand et al. (2005)
Rat/glomerulonephritis Reduces leukocyte rolling and adherence; decreases
neutrophil recruitment
Papayianni et al. (1995)
Rat/hyperalgesia Prolongs paw withdraw latency, reducing hyperalgesic
index, and reduces paw edema
Svensson et al. (2007)
Rat/pleuritis Shortens the duration of pleural exudation Bandeira-Melo et al. (2000)
Mouse/tumor growth Suppresses the growth of transplanted tumors in mice;
inhibits angiogenesis
Chen et al. (2010)
Mouse/allograft rejections Prevents acute rejection of vascularized cardiac and
renal allografts
Levy et al. (2011)
Mouse/arthritis Inhibits edema formation and PMN inﬂux, reduces
TNFa and LTB4 levels
Conte et al. (2010)
Rat/acute pancreatitis Reduces intercellular adhesion molecule 1 (ICAM-1)
and NF-kB p65 expression in the pancreas, and
expression of ICAM-1 in the lungs
Zhou et al. (2011)
Zebraﬁsh/mycobacterial infection Reduces bacterial burden and growth; improves
microbial containment by phagocytes
Tobin et al. (2012)
Resolvin E1 Mouse/dorsal air pouch Inhibits neutrophil recruitment Serhan et al. (2000a)
Mouse/peritonitis Inhibits neutrophil recruitment, regulates
chemokine/cytokine production, and promotes
lymphatic removal of phagocytes
Arita et al. (2005a),
Bannenberg et al. (2005), and
Schwab et al. (2007)
Rabbit/periodontitis Reduces PMN inﬁltration, prevents connective tissue
and bone loss, promotes healing of diseased tissues,
and promotes regeneration of lost soft tissue and bone
Hasturk et al. (2006, 2007)
Mouse/retinopathy Protects against neovascularization Connor et al. (2007)
Mouse/colitis Decreases PMN recruitment and pro-inﬂammatory
gene expression; improves survival and reduces weight
loss; favors LPS-detoxiﬁcation through induction of
intestinal alkaline phosphatase
Arita et al. (2005b), Campbell
et al. (2010), and Ishida et al.
(2010)
(Continued)
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Table 1 | Continued
SPM Disease model Mechanism of action Reference
Mouse/asthma Reduces IL -23 and IL -6, and increases IFNg and LXA4
in lungs to dampen airway inﬂammation; decreases
eosinophil and lymphocyte recruitment
Aoki et al. (2008, 2010) and
Haworth et al. (2008)
Mouse/obesity Regulates adipokines and protects against liver
steatosis
Gonzalez-Periz et al. (2009)
Mouse/inﬂammatory pain Inhibits spontaneous pain, and heat and mechanical
hypersensitivity
Xu et al. (2010)
Rat/cardiac ischemia/reperfusion injury Reduces infarct size Keyes et al. (2010)
Mouse/allograft rejections Prevents acute rejection of vascularized cardiac and
renal allografts
Levy et al. (2011)
Mouse/dry eye Promotes tear production, corneal epithelial
integrity, and decreases in inﬂammatory inducible
COX-2. RvE1 inhibits keratocyte transformation to
myoﬁbroblasts and lowers the number of
monocytes/macrophages
Li et al. (2010)
Mouse/herpes simplex virus Reduces severity of herpes simplex virus-induced
ocular lesions, reduces angiogenesis, and stromal
keratitis
Rajasagi et al. (2011)
Resolvin D1 Mouse/peritonitis Inhibits neutrophil recruitment; shortens resolution
interval; regulates miRNAs and target genes in
resolving exudates; reduces LTB4, PGD2, PGF2a,
andTXA2 in peritoneal exudates
Hong et al. (2003), Sun et al.
(2007), Spite et al. (2009b),
Recchiuti et al. (2011),
Krishnamoorthy et al. (2012),
and Norling et al. (2012)
Mouse/E. coli (peritoneal) and
S. aureus (skin) infection
Reduces bacterial titers and hypothermia; increased
survival; enhances microbial containment and killing
by phagocytes; lowers antibiotic requirement;
shortens resolution interval
Chiang et al. (2012)
Mouse/dorsal air pouch Inhibits neutrophil recruitment Serhan et al. (2002) and Hong
et al. (2003)
Mouse/kidney ischemia-reperfusion Protects from ischemia/reperfusion-induced kidney
damage and loss of function; regulates macrophages
Dufﬁeld et al. (2006)
Mouse/retinopathy Protects against neovascularization Connor et al. (2007)
Mouse/inﬂammatory pain Inhibits spontaneous pain, heat, and mechanical
hypersensitivity; selectively blocksTRPV1 and
TRPA1-mediated pain
Xu et al. (2010) and Park et al.
(2011)
Mouse/obesity Reduces inﬂammatory cytokines in adipose tissue
macrophages; stimulates M2 macrophage
differentiation; promotes resolution of adipose tissue
inﬂammation
Titos et al. (2011)
Mouse/T2 diabetes Reduces macrophage accumulation in adipose
tissue; ameliorates insulin sensitivity
Hellmann et al. (2011)
Rats/post-operative pain Reduces post-operative pain, tactile allodynia, and
hyperalgesia
Huang et al. (2011)
Mouse/pain Attenuates agonist-induced and inﬂammatory pain
behaviors; inhibitsTRPA1,TRPV3, andTRPV4
receptors; does not affect basal sensitivity
Bang et al. (2010) and Xu et al.
(2010)
Mouse/acute lung injury Blocks leukocyte inﬁltration and reduces cytokine
levels in BALF
Wang et al. (2011)
Mouse/corneal inﬂammation Reduces leukocyte inﬁltration and hemangiogenesis Jin et al. (2009)
(Continued)
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Table 1 | Continued
SPM Disease model Mechanism of action Reference
AT-RvD1 Mouse/colitis Reduces disease activity index, PMN number, and
pro-inﬂammatory levels
Bento et al. (2011)
Attenuates pain signals and behaviors by blocking
TRPV3
Bang et al. (2012)
Rats/arthritic pain Possesses anti-hyperalgesic effects upon systemic
administration. DecreasesTNF-a and IL -1b production
Lima-Garcia et al. (2011)
Resolvin D2 Mouse/peritonitis Blocks further PMN inﬁltration into the peritoneum Spite et al. (2009a)
Mouse/sepsis Prevents hypothermia, decreases bacterial load in the
blood and peritoneum, promotes survival
Spite et al. (2009a)
Mouse/colitis Improves disease activity index, weight loss, and
colonic PMN inﬁltration. Reduces pro-inﬂammatory
levels
Bento et al. (2011)
(Neuro)Protectin D1 Mouse/peritonitis Inhibits neutrophil recruitment and regulates
chemokine/cytokine production
Bannenberg et al. (2005) and
Serhan et al. (2006)
Promotes lymphatic removal of phagocytes; regulates
T-cell migration; enhances CCR5 expression on
apoptotic leukocytes
Ariel et al. (2005, 2006) and
Schwab et al. (2007)
Mouse/asthma Protects from lung damage, airway inﬂammation, and
hyper-responsiveness
Levy et al. (2007)
Human/asthma PD1 is generated in human asthmatic patients Levy et al. (2007)
Mouse/kidney ischemia/reperfusion Protects from ischemia/reperfusion-induced kidney
damage and loss of function; regulates macrophages
Dufﬁeld et al. (2006)
Mouse/retinopathy Protects against neovascularization Connor et al. (2007)
Rat/ischemic stroke Inhibits leukocyte inﬁltration, NF-kB, and COX-2
induction
Marcheselli et al. (2003)
Human/Alzheimer’s disease Diminished PD1 production in human Alzheimer’s
disease
Lukiw and Bazan (2008)
Mouse/liver injury Protects from necroinﬂammatory liver injury Gonzalez-Periz et al. (2009)
Mouse/Alzheimer’s disease Downregulates inﬂammatory genes; reduces
amyloidogenic Ab42 cleavage; protects from
apoptosis
Zhao et al. (2011)
Maresin-1 Mouse/peritonitis Blocks PMN inﬁltration into the peritoneum Serhan et al. (2009)
Planaria/tissue regeneration Stimulates tissue regeneration post surgical damage Serhan et al. (2012)
Mouse/pain Reduces pain Serhan et al. (2012)
monitor temporal changes in both leukocyte numbers and com-
position. Rapidly after zymosan injection, leukocytes inﬁltrated
the peritoneal cavity during the onset phase of acute inﬂam-
mation (4h), reaching a maximum (s22.0106) at s12h and
declined at 24–48h. Differential analysis with ﬂow cytometry
conﬁrmed that the majority of leukocytes in exudates at 4 and
12h were PMN (Ly-6Ghigh/CD11bC; s10.0106 cells at 4h
and s15106 cells at 12h). PMN number declined during the
resolution phase 24 and 48h after initiation of peritonitis. Con-
versely, resident peritoneal M(s (F4/80Ccells), which represent
the main leukocyte population in naive mice peritonea (Win-
yard and Willoughby, 2003), were not detected in exudates at 4h.
Monocytes(Ly-6Glow/CD11bhigh cells)graduallyincreasedat12h
and differentiated into M(s, consistent with their pro-resolution
functions(Gordon,2007),reachings60%ofexudateleukocytesat
48h.Becauseitisimportanttodeﬁneresolutioninunbiasedterms,
resolution indices, introduced by Bannenberg et al. (2005), were
calculated (i.e., )max s15.0106; Tmax s12h; )50 s7.5106;
T50 s30h; Ri s18h; Figure 7) to characterize the resolution
phaseanddeterminetemporalchangesinmiRNAexpressiondur-
ing this time interval. Hierarchical clustering grouped the s300
miRNAs examined into distinct clusters based on their relative
abundance at the different time intervals, indicating that speciﬁc
miRNAs are temporally regulated during acute inﬂammation and
its natural self-limited resolution.
In these studies, miR-21, miR-146b, miR-208a, and miR-219
were signiﬁcantly regulated at 12 and 24h compared to 4h
(Figure 7), suggesting a role in resolution. For instance, miR-21
provedtobecriticalfortheproductionofanti-inﬂammatoryIL-10
in experimental peritonitis (Sheedy et al., 2010), corroborating
our ﬁndings. Next,resolution indices were used to pinpoint RvD1
actions in resolution. RvD1,administered in its pro-drug carboxy
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FIGURE 6 | Strategy for identiﬁcation of RvD1-GPCR circuits. Self-limited
zymosan-stimulated mouse peritonitis was used to obtain resolving
exudates that were collected 4, 12, 24, and 48h after zymosan A injection
for temporal and differential analysis of leukocyte counts and phenotype,
miRNA real-time PCR analysis, and lipidomics as in Recchiuti et al. (2011)
and Krishnamoorthy et al. (2012). Candidate miRNAs, deﬁned as those that
were temporally and/or RvD1-regulated, were conﬁrmed using
bioinformatics and prediction of target genes, real-time PCR, as well as
overexpression in human M(s.The Ingenuity Pathway Analysis Software
database was used to identify circuits of molecules and biological functions
controlled by RvD1-regulated miRNAs and target genes (see text; Recchiuti
et al., 2011 for analysis details).
methyl ester form, signiﬁcantly lowered the )max (from 15.0 to
11.5106), and accelerated or shortened the Ri by s4h. Quan-
titative real-time PCR analyses carried out with exudates from
zymosan- and zymosan plus RvD1-treated mice revealed that
RvD1 temporally controls the speciﬁc sets of pro-resolving miR-
NAsmiR-21,miR-146b,miR-208a,andmiR-219(coinedresolution
miRs) in exudates in vivo. For translation to humans, actions
of RvD1 on these miRNAs were assessed in ALX/FPR2 and
DRV1/GPR32-overexpressing isolated human cells, namely M(,
the master regulators of resolution. Notably, RvD1 also regulated
miR-21, -146b, -208a, and 219 in a GPCR-dependent manner. In
ordertoidentifytargetmoleculesof RvD1-GPCR-regulatedmiRs,
we overexpressed miR-146b, -208a, and -219 in human M( for
real-time PCR analysis to assess which mRNAs were signiﬁcantly
regulated.
Since miRNAs can regulate mRNAs and protein levels of
hundreds of genes involved in biological processes (Bartel,
2009), miR-target genes were clustered using the Ingenuity
Pathway Analysis knowledge database based on their physi-
cal and/or functional interactions, creating the ﬁrst identiﬁed
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FIGURE 7 | Resolution indices and miRNA signature of resolution. (A)
Resolution indices were calculated as in (Bannenberg et al., 2005) using PMN
numbers in peritoneal exudates from mice treated with zymosan alone (red
line) and zymosan plus RvD1 (blue line) at indicated time intervals:T max, time
of maximum PMN inﬁltration ()max);T 50, time to achieve 50% reduction in
PMN number ()50) from )max; Ri, resolution interval (T 50  T max; time interval
betweenT max andT 50). RvD1, administered at the beginning of peritonitis,
signiﬁcantly lowers amplitude (i.e., )max) and duration (T 50) of PMN inﬁltration,
shortening the Ri by s4h. (B) Heat map cluster represents relative expression
of s300 mouse miRNAs from resolving exudates determined with real-time
PCR after normalization with housekeeping small RNAs (snoRNA251,
snoRNA202, snoRNA142, and Rnu6). Relative expression intensities are
indicated in a green-red color code based on DCt expression values (nD3
mice/group).Temporal and RvD1-regulated miRNAs are highlighted.
RvD1-GPCR-regulated gene networks involved in inﬂammation
and resolution. For instance, miR-146 networks 1 and 3 included
genes of the NF-kB activation pathway (e.g., IkB kinase and
tumor necrosis factor receptor-associated factor 6) and innate
response to pathogens (e.g., Toll-like receptors, S100 protein, C-
reactive protein, peptidoglycan recognition protein; Figure 8A).
Several cytokines and chemokines (IL-8, 10, 12, interferon-a and
b) belonged to the miR-146b network 2 (Figure 8A). NF-kB is
a critical transcription factor involved in regulation of cell func-
tions in inﬂammation and resolution (Lawrence et al., 2001). Of
interest,RvD1inhumanmonocytesreducesthenucleartransloca-
tion of NF-kB,TNF-a induced phosphorylation of IkB (Recchiuti
et al., 2011), counteracts NF-kB activation in ALX/FPR2 and
DRV1/GPR32 recombinant cells (Krishnamoorthy et al., 2010),
dampensacuteinﬂammationinmurinedorsalairpouchesevoked
bylocaladministrationof TNF-a(Serhanetal.,2002),anddown-
regulates IKK levels in murine peritonitis (Recchiuti et al., 2011).
Therefore, regulation of miRNAs and the TNF-a-NF-kB axis
seems to be a key component in the RvD1-GPCR downstream
signaling network.
The miRNA miR-208a downregulates CD14, CD40 ligand,
PGI2 receptor, thromboxane A2 receptor, and programmed cell
death (Recchiuti et al., 2011; Figure 8B), a tumor suppressor
molecule that acts as a translational repressor of IL-10 (Sheedy
etal.,2010),consistentwiththeexistenceof aseedregionformiR-
208a in the 30 UTR of PDCD4. Notably,in self-limited peritonitis,
RvD1reducedPDCD4andincreasedIL-10production,providing
in vivo correlates of RvD1-miR-dependent gene regulations.
The miR-219 network includes CD14 and 5-LO (Figure8C),a
key enzyme for the biosynthesis of LTs, and SPMs. In addition, a
signiﬁcant reduction in 5-LO protein levels and LTB4 production
wasfoundinhumanM(overexpressingtheRvD1-regulatedmiR-
219, translating ﬁndings in mouse peritonitis to the human M(
cell system (Recchiuti et al., 2011). Endogenous regulatory mech-
anisms of 5-LO are of wide interest given the important roles of
LTs, LXs, and Rvs in inﬂammation and resolution (Samuelsson,
1983; Serhan et al., 2002). In addition to transcriptional regu-
lation by cytokines and growth factors (Radmark et al., 2007),
miR-219 can provide a rapid mean to balance the abundance of
5-LO protein in cells under dynamic conditions such as during
inﬂammation.
RvD1 actionswere also tested ingenetically engineered micein
order to obtain further evidence of ALX/FPR2-dependent action.
Transgenic mouse colonies in which human ALX/FPR2 gene was
placed under control of a CD11b promoter that drives trans-
gene expression in mature murine myeloid cells were created
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FIGURE 8 |Translation of RvD1-dependent miRNA circuits in human cells. RvD1-GPCR gene networks connecting target genes of miR-146b (A), miR-208a
(B), and miR-219 (C). Genes that are signiﬁcantly down regulated in each network are indicated in red.
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FIGURE 9 | Evidence forALX/FPR2-RvD1-dependent miRNA
pathways in vivo. Reduction in (A) PMN inﬁltration by RvD1 is
signiﬁcantly higher in myeloid-driven human ALX-transgenic (Tg) mice
challenged with zymosan (1mg/mouse, i.p., 24h) than non-Tg
littermates. Results are meanSEM from three mice/group (*P <0.05
vs. non-Tg). (B) Relative expression of miR-208a determined in resolving
exudates 24h after zymosan alone or zymosan plus RvD1 administration
in hALX-Tg or non-Tg littermates (meanSEM, nD3 mice/group;
**P <0.05 vs. non-Tg zymosan group; #, P <0.05 vs. hALX-Tg zymosan
group). (C) miR-208a expression in peritoneal exudates (24h) from
ALX/FPR2 knockout mice treated with zymosan alone or zymosan plus
RvD1.
(Devchand et al., 2003). Interestingly, total peritoneal leukocytes
at24hperitonitisweresigniﬁcantlylowerinALX/FPR2transgenic
mice treated with zymosan alone compared to non-transgenic lit-
termates,andRvD1administrationresultedinafurthersigniﬁcant
decrease (s53% reduction) in peritoneal exudate leukocyte num-
bers in ALX/FPR2 transgenic mice compared to non-transgenic
littermates (Figure 9). Quantitative PCR analysis of miRNAs
isolated from peritoneal lavages collected 24h post injection of
zymosan showed that RvD1 signiﬁcantly upregulated identiﬁed
resolution miRs miR-208a and miR-219 in vivo (Recchiuti et al.,
2011), whereas it does not appear to regulate miR-21, miR-146b,
and miR-302d (Figure 9). To further investigate ALX/FPR2-
dependent actions of RvD1 in vivo, it was next tested whether
RvD1 can regulate some of these miRNAs inALX/FPR2 knockout
mice, where LXA4 did not regulate leukocyte trafﬁcking (Dufton
et al., 2010). In ALX/FPR2 /  mice, RvD1 did not regulate PMN
inﬁltration, consistent with recent results (Norling et al., 2012),
nor did it signiﬁcantly alter miR-208a or miR-219 expression at
24h (Figure 9).
Takentogether,theseresultsindicatethatRvD1controlsleuko-
cyte inﬁltration and speciﬁc resolution phase miRs in acute
inﬂammation in an ALX/FPR2-dependent manner in mice and
DRV1/GPR32-dependent in isolated human cells.
SUMMATION AND CONCLUSION
It is now eminently clear that the acute inﬂammatory response
of the host is a highly coordinated defensive response and its
complete resolution is the ideal outcome. This ideal outcome is
achieved in self-limited inﬂammation by activation of endoge-
nous resolution programs that are governed in part by reso-
lution phase local chemical mediators. Excessive inﬂammation
can lead to chronic disorders and host damage. LM from AA,
such as PGs and LTs, can amplify the inﬂammatory response,
and PGE2 and D2 initiate the “class switch” that leads to the
biosynthesis of LXA4, the ﬁrst member of the new genus of SPM.
SPM include several families of LM such as E-and D-series Rv
(neuro)PD, and the youngest family, the MaR, which are biosyn-
thesizedfromessential&-3fattyacids.Of interestinexperimental
animal models of disease, each of the SPM can accelerate the
resolution process when administered in vivo, and their bioac-
tions are highly stereospeciﬁc, GPCR-mediated, and exerted at
low doses. SPM also reduce pain and promote tissue regenera-
tion, the ultimate goal of complete return to homeostasis. Results
from the ﬁrst human clinical Phase I and II trial with a Rv
analog appear encouraging and can open new opportunities for
resolution pharmacology based on endogenous mediators to ter-
minateinﬂammationandtreatinﬂammation-relateddiseases.We
trust that more human trials will be launched to test the notion
that stimulating resolution mechanisms can improve disease and
health status.
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